-
Mashup Score: 71
AbstractPurpose:. Treatment of homologous recombination repair–deficient (HRD)-tumors with PARP inhibitors has the potential to further increase tumor immunogenicity, suggesting a synergistic effect with immunotherapy. Here we present the preliminary results of niraparib in combination with dostarlimab for pleural mesothelioma (PM) or non–small cell lung cancer (NSCLC) harboring HRR mutations.Experimental Design:. UNITO-001 is a phase II, prospective, study aiming to investigate the combination of niraparib plus dostarlimab in pretreated patients with HRD and programmed death ligand-1 (PD-L1) ≥1% NSCLC and/or PM. The primary endpoint is progression-free survival (PFS).Results:. Seventeen of 183 (10%) screened patients (12 PM and 5 NSCLC) were included. The objective response rate (ORR) was 6% [95% confidence interval (CI): 0.1–28.7] and the disease control rate (DCR) was 53% (95% CI: 27.8–77). Median PFS was 3.1 (95% CI: 2.7–N.A) and median overall survival (OS) was 4.2 (95% CI: 1.58–N
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
Positive phase III trials are not truly practice changing if they do not accurately inform on the best options for patients
Source: ascopubs.orgCategories: Latest Headlines, UrologyTweet-
RT @Dr_RaviMadan: https://t.co/b0wpz7z8yf #PARP inhibitors in #ProstateCancer ? https://t.co/zGDkQUb6e9
-
-
Mashup Score: 4
Positive phase III trials are not truly practice changing if they do not accurately inform on the best options for patients
Source: ascopubs.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
https://t.co/b0wpz7z8yf #PARP inhibitors in #ProstateCancer ? https://t.co/zGDkQUb6e9 https://t.co/ji7xJ4d8Fe
-
“Despite the regulatory greenlight, there remain significant gaps in data & clarity regarding the optimal timing of #PARP inhibitor tx for pts w/ #ProstateCancer whose tumors have HRRms.” @FatimaKarzai@heatherhcheng @vanderweelemd https://t.co/b0wpz7z8yf
-
-
Mashup Score: 12Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting - 8 month(s) ago
Preclinical models of germline BRCA–associated pancreatic ductal adenocarcinoma (glBRCA PDAC) that reflect different clinical time points along the response spectrum of platinum/PARP inhibitor treatment were developed and used to evaluate mechanisms of resistance to these therapies.
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
From the August issue— Spectrum of Response to Platinum and #PARP Inhibitors in Germline #BRCA–Associated #PancreaticCancer in the Clinical and Preclinical Setting, by @ChaniStossel, Maria Raitses-Gurevich, Talia Golan et al. https://t.co/Vk7EFR0QTM @sheba_medical @TelAvivUni https://t.co/Q3EXZ5fsfE
-
-
Mashup Score: 0Kidney function in patients with ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors - 8 month(s) ago
AbstractBackground. Poly (ADP-ribose) polymerase inhibitors (PARPi) have revolutionized the treatment of ovarian cancer; however, real-world data on kidney func
Source: academic.oup.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
This study in @JNCI_Now investigates the incidence of acute kidney injury (AKI) in #ovariancancer patients treated with #olaparib or #niraparib. They found 22.3% developed AKI but only 3.3% had AKI related to the #PARP inhibitor. #gyncsm Read more: https://t.co/qiRAfsMxDK https://t.co/2iYEn8jvVP
-
-
Mashup Score: 3Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting - 9 month(s) ago
AbstractGermline BRCA–associated pancreatic ductal adenocarcinoma (glBRCA PDAC) tumors are susceptible to platinum and PARP inhibition. The clinical outcomes of 125 patients with glBRCA PDAC were stratified based on the spectrum of response to platinum/PARP inhibition: (i) refractory [overall survival (OS) <6 months], (ii) durable response followed by acquired resistance (OS <36 months), and (iii) long-term responders (OS >36 months). Patient-derived xenografts (PDX) were generated from 25 patients with glBRCA PDAC at different clinical time points. Response to platinum/PARP inhibition in vivo and ex vivo culture (EVOC) correlated with clinical response. We deciphered the mechanisms of resistance in glBRCA PDAC and identified homologous recombination (HR) proficiency and secondary mutations restoring partial functionality as the most dominant resistant mechanism. Yet, a subset of HR-deficient (HRD) patients demonstrated clinical resistance. Their tumors displayed basal-like molecular s
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ICYMI— Spectrum of Response to Platinum and #PARP Inhibitors in Germline #BRCA–Associated #PancreaticCancer in the Clinical and Preclinical Setting, by @ChaniStossel, Maria Raitses-Gurevich Talia Golan et al. https://t.co/dKqtorhfSw @sheba_medical @TelAvivUni https://t.co/c1x9hjKqug
-
-
Mashup Score: 0
A phase 1 clinical trial could provide biomarker clues to help guide future studies.
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet-
#PARP/#ATR inhibitor combo shows hints of promise in children with #tumors👇 https://t.co/1F5M3bDfJr @MDedgeHemOnc @Jimkling #PARPATRInhibitor https://t.co/llandcefo8
-
-
Mashup Score: 4
Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) provided significant antitumor activity in various tumors, mainly carrying deleterious mutations of BRCA1/BRCA2 genes. Only few data are available regarding the cardiac and vascular safety profile of this drug class. We carried out a meta-analysis for assessing the incidence and relative risk (RR) of major adverse cardiovascular events…
Source: Esmo OpenCategories: Hem/Oncs, Latest HeadlinesTweet-
Clinically important topic: Major adverse cardiac events and #cardiovascular toxicity with #PARP inhibitors-based therapy for solid #tumors: a systematic review and safety meta-analysis. Just published in @ESMO_Open by @myESMO https://t.co/TrvbKLsYI7
-
-
Mashup Score: 0
As determined on the basis of imaging, PFS was 37% better for talazoparib plus enzalutamide than for enzalutamide monotherapy.
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet-
#Talazoparib add-on improves outcomes in metastatic #ProstateCancer 👉https://t.co/otLJknDfxP @MDedgeHemOnc #PARP #mCRPC https://t.co/s8fYuZLQQT
-
-
Mashup Score: 1The Uromigos: Episode 210: Christmas Prostate Cancer Debate - olaparib and abiraterone in selected or unselected patients on Apple Podcasts - 1 year(s) ago
Show The Uromigos, Ep Episode 210: Christmas Prostate Cancer Debate – olaparib and abiraterone in selected or unselected patients – Dec 22, 2022
Source: Apple PodcastsCategories: Hem/Oncs, Latest HeadlinesTweet-
Looking for a gr8 discussion on #PARP inhibitors in #prostatecancer? 👂this terrific debate between @Daniel_J_George & @Silke_Gillessen on @Uromigos w @tompowles1 & @brian_rini. Great listen esp ahead of #TALAPRO2 results at @ASCO #GU23 from @neerajaiims! https://t.co/BQFZu6Eh9O
-
Disappointing results with #PARP inhibition plus immunotherapy in homologous recombination repair deficient mesothelioma or NSCLC @CCR_AACR. Niraparib plus dostarlimab in HRD mt mesothelioma (n=12) or NSCLC (n=5) with RR 6%, mPFS 3.1m, mOS 4.2m. https://t.co/ZxpINvSrmf